Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 1,433–1,440 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
DBV Technologies S.A. Viaskin Peanut - (VITESSE) Peanut allergy BLA Filing Ongoing Transdermal Immunology
Deciphera Pharmaceuticals Inc. QINLOCK vs sunitinib - (INSIGHT) Gastrointestinal stromal tumor (GIST) patients with mutations in KIT exon 11 and 17/18 Phase 3 oral Oncology
Deciphera Pharmaceuticals Inc. Vimseltinib (DCC-3014) - (MOTION) Tenosynovial Giant Cell tumor NDA Filing Ongoing Oral Oncology
Deciphera Pharmaceuticals Inc. Vimseltinib (DCC-3014) Graft versus host disease (cGvHD) Phase 2 Enrollment Initiation Oral Immunosuppressant
Deciphera Pharmaceuticals Inc. Vimseltinib (DCC-3014) Graft versus host disease (cGvHD) Phase 2 Enrollment Initiation Oral Immunosuppressant
Deciphera Pharmaceuticals Inc. QINLOCK (ripretinib) and MEKTOVI (​binimetinib) Gastrointestinal stromal tumor (GIST) Phase 2 oral Oncology
Deciphera Pharmaceuticals Inc. QINLOCK (ripretinib) and MEKTOVI (​binimetinib) Gastrointestinal stromal tumor (GIST) Phase 2 oral Oncology
Deciphera Pharmaceuticals Inc. QINLOCK (ripretinib) - (INTRIGUE) Gastrointestinal Stromal Tumors (GIST) - second-line Phase 3 Data Released Oral Oncology